News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
News Mylan finalises $465m deal with US government over EpiPen Mylan finalises rebate deal with US government.
News Novo Nordisk may drop US insulin price as Sanofi suffers Biosimilar Lantus is causing rivals to cut prices to compete
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
